Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma
Authors
Keywords
Uveal melanoma, SNS-032, Transcription, Apoptosis, Cancer stem-like cells, Self-renewal, KLF4, Cell motility, RhoA, Liver metastasis
Journal
Molecular Cancer
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-16
DOI
10.1186/s12943-019-1070-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A novel regulatory function of CDKN1A/p21 in TNFα-induced matrix metalloproteinase 9-dependent migration and invasion of triple-negative breast cancer cells
- (2018) Magdalena Zaremba-Czogalla et al. CELLULAR SIGNALLING
- Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
- (2018) Richard D. Carvajal et al. JOURNAL OF CLINICAL ONCOLOGY
- Positively selected enhancer elements endow osteosarcoma cells with metastatic competence
- (2018) James J Morrow et al. NATURE MEDICINE
- GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma
- (2018) Amanda R. Moore et al. Cell Reports
- Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy
- (2017) Giovanni Schinzari et al. MELANOMA RESEARCH
- Transcription regulation by the Mediator complex
- (2017) Julie Soutourina NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts
- (2017) Ronan Crépin et al. Pigment Cell & Melanoma Research
- The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo
- (2017) Jingfeng Zhou et al. Theranostics
- Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells
- (2017) Yangling Li et al. Stem Cell Reports
- Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing
- (2016) Beryl Royer-Bertrand et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Metastatic disease from uveal melanoma: treatment options and future prospects
- (2016) Richard D Carvajal et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Autocrine Secretion of Progastrin Promotes the Survival and Self-Renewal of Colon Cancer Stem-like Cells
- (2016) J. Giraud et al. CANCER RESEARCH
- Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns
- (2016) Hans E. Grossniklaus et al. HUMAN PATHOLOGY
- Metastatic colonization by circulating tumour cells
- (2016) Joan Massagué et al. NATURE
- ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA
- (2016) A Talamillo et al. ONCOGENE
- Cancer Stem Cells: Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy Resistance
- (2015) V. Adorno-Cruz et al. CANCER RESEARCH
- Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells
- (2015) J. Cao et al. CANCER RESEARCH
- CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
- (2015) Yubao Wang et al. CELL
- Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
- (2014) Fa-Xing Yu et al. CANCER CELL
- Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry
- (2014) Xiaodong Feng et al. CANCER CELL
- The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo
- (2014) GUI’E XIE et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target
- (2014) Nabil Amirouchene-Angelozzi et al. Molecular Oncology
- Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
- (2014) Fariba Némati et al. PLoS One
- Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
- (2013) O. Surriga et al. MOLECULAR CANCER THERAPEUTICS
- Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations
- (2013) X Chen et al. ONCOGENE
- Cyclin-Dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells
- (2012) Y. Wu et al. CLINICAL CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Uveal Melanoma: Trends in Incidence, Treatment, and Survival
- (2011) Arun D. Singh et al. OPHTHALMOLOGY
- Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors
- (2010) F. Nemati et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
- (2010) Wei-Gang Tong et al. JOURNAL OF CLINICAL ONCOLOGY
- Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis
- (2010) Chia-Hsin Chan et al. NATURE CELL BIOLOGY
- Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
- (2010) J. W. Harbour et al. SCIENCE
- Expression and distribution of MMPs and TIMPs in human uveal melanoma
- (2008) K. Lai et al. EXPERIMENTAL EYE RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started